ArticleCancers2025
AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia, and Its Correlation with Morphofunctional Assessment Techniques.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pragmatic Screening for Sarcopenia in Non-Small Cell Lung Cancer: Development and Internal Validation of a Prospective Risk Model Integrating T12 CT Indices and Routine Clinical Variables.Cancer medicine · 2026Article
- Radiation dose has no significant impact on CT-based bone mineral density measurements in a large-animal model.Scientific reports · 2026Article
- Nutritional ultrasound cut off for predicting complications and mortality in lung cancer patients: a multicenter longitudinal study from the VALONC project.Frontiers in nutrition · 2026Article
- Impact of Nutritional Status on Severe Radiation-Induced Mucositis in Oropharyngeal Cancer Patients Undergoing Chemo-Radiotherapy.Nutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia and low muscle mass are prevalent and prognostically relevant in patients with lung cancer, yet their diagnosis remains challenging in routine clinical practice. Opportunistic assessment using computed tomography (CT) has emerged as a valuable tool for body composition evaluation. We aimed to assess the utility of thoracic CT at T12 and T4 levels in identifying sarcopenia and low muscle mass and explore their correlation with morphofunctional tools such as bioelectrical impedance vector analysis (BIVA), nutritional ultrasound (NU), and functional performance tests.
methodsIn this prospective observational study, 80 patients with lung cancer were evaluated at diagnosis. Body composition was assessed using BIVA-, NU-, and CT-derived parameters at T12 and T4 levels. Functional status was measured using the Timed Up and Go (TUG) and 30-Second Chair Stand Test. Sarcopenia was defined according to EWGSOP2 criteria.
resultsSarcopenia was identified in 20% of patients. CT-derived indices at T12CT demonstrated better diagnostic performance than T4CT. For detecting low muscle mass, the optimal SMI cut-off values were SMI_T12CT < 31.98 cm
conclusionsCT-derived body composition assessment, particularly at the T12 level, shows good correlation with morphofunctional tools and may offer a reliable and timely alternative for identifying sarcopenia and low muscle mass in patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.